Pediatric Intestinal Failure: Nutrition,Pharmacologic,and Surgical Approaches

Abstract

Intestinal failure (IF) is a condition where there is insufficient functional bowel to allow for adequate nutrient and fluid absorption to sustain adequate growth in children. Several etiologies can predispose to IF, including necrotizing enterocolitis, gastroschisis, and intestinal atresias. Intestinal rehabilitation can be seen as a 3-pronged strategy merging nutrition, pharmacologic, and surgical approaches to achieve the ultimate goal of enteral nutrition. Nutrition approaches should seek to facilitate transition from parenteral nutrition (PN) to enteral nutrition because prolonged use of PN is associated with severe morbidity and mortality. Enteral nutrition, on the other hand, promotes and enhances an adaptive response in the intestine. Medications used in the treatment of IF may help alleviate symptoms of diarrhea, bacterial overgrowth, and gastrointestinal dysmotility. Surgical procedures, such as longitudinal intestinal lengthening and tapering (LILT) or serial transverse enteroplasty (STEP), can increase mucosal surface area and may enhance intestinal adaptation. IF is a difficult disease process with a complex patient population and is best guided through this 3-pronged approach by a multidisciplinary team featuring surgeons, gastroenterologists, dietitians, pharmacists, and nurses.

Get full access to this article

View all access options for this article.

References

Btaiche IF, Khalidi N. Parenteral nutrition-associated liver complications in children. Pharmacotherapy. 2002 ;22:188– 211.

Javid PJ, Greene AK, Garza J, et al. The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg. 2005 ;40:1446– 1453.

Ferezou J, Bach AC. Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions. Nutrition. 1999 ;15:44– 50.

Mayer K, Fegbeutel C, Hattar K, et al. Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med. 2003 ;29:1472– 1481.

Utter S, Duggan C. Short bowel syndrome. In: Hendricks KM, Duggan C, eds. Manual of Pediatric Nutrition. 4th ed. Hamilton, Ontario, Canada: BC Decker; 2005:718– 735.

Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006 ;118:e197– e201.

Kollman KA, Lien EL, Vanderhoof JA. Dietary lipids influence intestinal adaptation after massive bowel resection. J Pediatr Gastroenterol Nutr. 1999;28:41– 45.

Andorsky DJ, Lund DP, Lillehei CW, et al. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr. 2001 ;139:27– 33.

Parker P, Stroop S, Greene H. A controlled comparison of continuous versus intermittent feeding in the treatment of infants with intestinal disease. J Pediatr. 1981 ;99:360– 364.

10.

Wessel JJ, Kocoshis SA. Nutritional management of infants with short bowel syndrome. Semin Perinatol. 2007 ;31:104– 111.

11.

Sundaram A, Koutkia P, Apovian CM. Nutritional management of short bowel syndrome in adults. J Clin Gastroenterol. 2002 ;34:207– 220.

12.

Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel. Lancet. 1994 ;343:373– 376.

13.

Ovesen L, Chu R, Howard L. The influence of dietary fat on jejunostomy output in patients with severe short bowel syndrome. Am J Clin Nutr. 1983;38:270– 277.

14.

Woolf GM, Miller C, Kurian R, Jeejeebhoy KN. Diet for patients with a short bowel: high fat or high carbohydrate? Gastroenterology. 1983 ;84:823– 828.

15.

Cosnes J, Evard D, Beaugerie L, Gendre JP, Le Quintrec Y. Improvement in protein absorption with a small-peptide-based diet in patients with high jejunostomy. Nutrition. 1992 ;8:406– 411.

16.

Levy E, Frileux P, Sandrucci S, et al. Continuous enteral nutrition during the early adaptive stage of the short bowel syndrome. Br J Surg. 1988;75:549– 553.

17.

McIntyre PB, Fitchew M, Lennard-Jones JE. Patients with a high jejunostomy do not need a special diet. Gastroenterology. 1986 ;91:25– 33.

18.

Ksiazyk J, Piena M, Kierkus J, Lyszkowska M. Hydrolyzed versus nonhydrolyzed protein diet in short bowel syndrome in children. J Pediatr Gastroenterol Nutr. 2002 ;35:615– 618.

19.

Vanderhoof JA. New and emerging therapies for short bowel syndrome in children. J Pediatr Gastroenterol Nutr. 2004 ;39 (Suppl 3):S769– S771.

20.

Bines J, Francis D, Hill D. Reducing parenteral requirement in children with short bowel syndrome: impact of an amino acid-based complete infant formula. J Pediatr Gastroenterol Nutr. 1998 ;26:123– 128.

21.

Matarese LE, O'Keefe SJ, Kandil HM, Bond G, Costa G, AbuElmagd K. Short bowel syndrome: clinical guidelines for nutrition management. Nutr Clin Pract. 2005 ;20:493– 502.

22.

Jeppesen PB, Mortensen PB. The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. Gut. 1998;43:478– 483.

23.

Nightingale JM, Lennard-Jones JE, Gertner DJ, Wood SR, Bartram CI. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut. 1992 ;33:1493– 1497.

24.

Bond JH, Currier BE, Buchwald H, Levitt MD. Colonic conservation of malabsorbed carbohydrate. Gastroenterology. 1980 ;78:444– 447.

25.

Goulet O, Ruemmele F, Lacaille F, Colomb V. Irreversible intestinal failure. J Pediatr Gastroenterol Nutr. 2004 ;38:250– 269.

26.

Lennard-Jones JE. Review article: practical management of the short bowel. Aliment Pharmacol Ther. 1994 ;8:563– 577.

27.

Heel RC, Brogden RN, Speight TM, Avery GS. Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs. 1978;15:33– 52.

28.

Remington M, Malagelada JR, Zinsmeister A, Fleming CR. Abnormalities in gastrointestinal motor activity in patients with short bowels: effect of a synthetic opiate. Gastroenterology. 1983;85 : 629–636.

29.

Karamanolis G, Tack J. Promotility medications: now and in the future. Dig Dis. 2006 ;24:297– 307.

30.

Jones MP. Access options for withdrawn motility-modifying agents. Am J Gastroenterol. 2002 ;97:2184– 2188.

31.

Scarpignato C, Pelosini I. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can J Gastroenterol. 1999 ;13(Suppl A):50A– 65A.

32.

Banh HL, MacLean C, Topp T, Hall R. The use of tegaserod in critically ill patients with impaired gastric motility. Clin Pharmacol Ther. 2005;77:583– 586.

33.

Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001 ;15:1655– 1666.

34.

Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med.1996 ;334:246– 254.

35.

Nehra V, Camilleri M, Burton D, Oenning L, Kelly DG. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol. 2001 ;96:1494– 1498.

36.

Sinha L, Liston R, Testa HJ, Moriarty KJ. Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther. 1998 ;12:839– 844.

37.

Kaufman SS, Loseke CA, Lupo JV, et al. Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. J Pediatr. 1997 ;131:356– 361.

38.

Puwanant M, Mo-Suwan L, Patrapinyokul S. Recurrent D-lactic acidosis in a child with short bowel syndrome. Asia Pac J Clin Nutr. 2005;14:195– 198.

39.

Dibaise JK, Young RJ, Vanderhoof JA. Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol. 2006;4:11– 20.

40.

Demirogullari B, Poyraz A, Cirak MY, et al. Effects of hyperosmolar agents—lactulose, lactitol, sodium phosphate and polyethylene glycol—on cecal coliform bacteria during traditional bowel cleansing: an experimental study in rats. Eur Surg Res. 2004 ;36:159– 164.

41.

Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr. 1998 ;27:155– 160.

42.

Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 2001;73(2 Suppl): 430S–436S.

43.

Richette P, Ayoub G, Bardin T, Bouvet S, Orcel P, Badran AM. Hypomagnesemia and chondrocalcinosis in short bowel syndrome. J Rheumatol. 2005;32:2434– 2436.

44.

Howard Payne J, De Wing LT, Commons RR. Metabolic observations in patients with jejunocolic shunts: 1963. Nutr Hosp. 2006 ; 21:209– 221.

45.

Mager DR, McGee PL, Furuya KN, Roberts EA. Prevalence of vitamin K deficiency in children with mild to moderate chronic liver disease. J Pediatr Gastroenterol Nutr. 2006 ;42:71– 76.

46.

Alvarez F, Cresteil D, Lemonnier F, Lemonnier A, Alagille D. Plasma vitamin E levels in children with cholestasis. J Pediatr Gastroenterol Nutr. 1984;3:390– 393.

47.

Peterson CA, Ney DM, Hinton PS, Carey HV. Beneficial effects of insulin-like growth factor I on epithelial structure and function in parenterally fed rat jejunum. Gastroenterology. 1996 ;111:1501– 1508.

48.

Gu Y, Wu ZH, Xie JX, Jin DY, Zhuo HC. Effects of growth hormone (rhGH) and glutamine supplemented parenteral nutrition on intestinal adaptation in short bowel rats. Clin Nutr. 2001 ;20:159– 166.

49.

Ziegler TR, Mantell MP, Chow JC, Rombeau JL, Smith RJ. Gut adaptation and the insulin-like growth factor system: regulation by glutamine and IGF-I administration. Am J Physiol. 1996 ;271(5 Pt 1):G866– G875.

50.

Wu G, Knabe DA, Yan W, Flynn NE. Glutamine and glucose metabolism in enterocytes of the neonatal pig. Am J Physiol. 1995 ;268(2 Pt 2):R334– R342.

51.

Seguy D, Vahedi K, Kapel N, Souberbielle JC, Messing B. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology. 2003 ;124:293– 302.

52.

Byrne TA, Morrissey TB, Nattakom TV, Ziegler TR, Wilmore DW. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. JPEN J Parenter Enteral Nutr. 1995;19:296– 302.

53.

Byrne TA, Wilmore DW, Iyer K, et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg. 2005;242 :655– 661.

54.

Scolapio JS. Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomized, controlled study. JPEN J Parenter Enteral Nutr. 1999 ;23:309– 313.

55.

Jeppesen PB, Szkudlarek J, Hoy CE, Mortensen PB. Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study. Scand J Gastroenterol. 2001 ;36:48– 54.

56.

Scolapio JS, Camilleri M, Fleming CR, et al. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology. 1997 ; 113:1074– 1081.

57.

Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg. 1997 ;225:88– 96.

58.

Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut. 2000 ;47:199– 205.

59.

Severijnen R, Bayat N, Bakker H, Tolboom J, Bongaerts G. Enteral drug absorption in patients with short small bowel: a review. Clin Pharmacokinet. 2004;43:951– 962.

60.

Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad SciUSA. 1996;93:7911– 7916.

61.

Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 1998;275(5 Pt 1): G911–G921.

62.

Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol. 1998;33:828– 832.

63.

Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab. 1999 ;84:2513– 2517.

64.

Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001 ;120:806– 815.

65.

Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54:1224– 1231.

66.

Bianchi A. Intestinal loop lengthening: a technique for increasing small intestinal length. J Pediatr Surg. 1980 ;15:145– 151.

67.

Ienaga T, Kimura K, Hashimoto K, Lee SC, Brakstad M, Soper RT. Isolated bowel segment (Iowa model 1): technique and histological studies. J Pediatr Surg. 1990 ;25:902– 904.

68.

Georgeson K, Halpin D, Figueroa R, Vincente Y, Hardin W Jr. Sequential intestinal lengthening procedures for refractory short bowel syndrome. J Pediatr Surg. 1994 ;29:316– 321.

69.

Bianchi A. From the cradle to enteral autonomy: the role of autologous gastrointestinal reconstruction. Gastroenterology. 2006 ;130(2 Suppl 1):S138– S146.

70.

Hosie S, Loff S, Wirth H, Rapp HJ, von Buch C, Waag KL. Experience of 49 longitudinal intestinal lengthening procedures for short bowel syndrome. Eur J Pediatr Surg. 2006 ;16:171– 175.

71.

Kim HB, Fauza D, Garza J, Oh JT, Nurko S, Jaksic T. Serial transverse enteroplasty (STEP): a novel bowel lengthening procedure. J Pediatr Surg. 2003 ;38:425– 429.

72.

Kim HB, Lee PW, Garza J, Duggan C, Fauza D, Jaksic T. Serial transverse enteroplasty for short bowel syndrome: a case report. J Pediatr Surg. 2003;38:881– 885.

73.

Piper H, Modi BP, Kim HB, Fauza D, Glickman J, Jaksic T. The second STEP: the feasibility of repeat serial transverse enteroplasty. J Pediatr Surg. 2006;41:1951– 1956.

74.

Modi BP, Javid PJ, Jaksic T, et al. First report of the International Serial Transverse Enteroplasty Data Registry: indications, efficacy, and complications. J Am Coll Surg. 2007 ;204:365– 371.

75.

Modi BP, Langer M, Duggan C, Kim HB, Jaksic T. Serial transverse enteroplasty for management of refractory D-lactic acidosis in short-bowel syndrome. J Pediatr Gastroenterol Nutr. 2006 ;43:395– 397.

76.

Wales PW, Dutta S. Serial transverse enteroplasty as primary therapy for neonates with proximal jejunal atresia. J Pediatr Surg. 2005;40:E31– E34.

77.

Ismail A, Alkadhi A, Alnagaar O, Khirate A. Serial transverse enteroplasty in intestinal atresia management. J Pediatr Surg. 2005;40:E5– E6.

78.

Chang RW, Javid PJ, Oh JT, et al. Serial transverse enteroplasty enhances intestinal function in a model of short bowel syndrome. Ann Surg. 2006 ;243:223– 228.

79.

O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006 ;4:6– 10.

80.

Barksdale EM, Stanford A. The surgical management of short bowel syndrome. Curr Gastroenterol Rep. 2002 ;4:229– 237.

81.

Sudan D. Cost and quality of life after intestinal transplantation. Gastroenterology. 2006 ;130(2 Suppl 1):S158– S162.

82.

The Intestinal Transplant Registry. Available at: http://www.intestinaltransplant.org. Accessed June 30, 2007.